^
    3d
    ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Adaptimmune | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    16d
    STELLA: Administration of Donor MultiTAA-Specific T Cells for ALL (clinicaltrials.gov)
    P1, N=40, Completed, Baylor College of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MME (Membrane Metalloendopeptidase)
    |
    MultiTAA T cell therapy
    2ms
    IMC-C103C-101: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Immunocore Ltd | N=75 --> 0 | Terminated --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    |
    Tecentriq (atezolizumab) • IMC-C103C
    2ms
    Afamitresgene Autoleucel: First Approval. (PubMed, Mol Diagn Ther)
    In August 2024, afamitresgene autoleucel was approved in the USA under accelerated approval for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P or -A*02:06P positive and whose tumour expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. This article summarizes the milestones in the development of afamitresgene autoleucel leading to this first approval for the treatment of advanced synovial sarcoma.
    Review • Journal • IO Companion diagnostic
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    |
    Tecelra (afamitresgene autoleucel)
    3ms
    Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel (clinicaltrials.gov)
    P=N/A, N=0, Available, Adaptimmune
    New trial
    |
    Tecelra (afamitresgene autoleucel)
    3ms
    PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
    P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Trial primary completion date: Dec 2025 --> Jul 2024
    Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • pemetrexed • PDC*lung
    4ms
    A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Genentech, Inc. | N=210 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    Actemra IV (tocilizumab)
    4ms
    PANACEA: MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Marker Therapeutics, Inc.
    New P1 trial • Metastases
    5ms
    FDA Grants Thermo Fisher Scientific SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma (Businesswire)
    "Thermo Fisher Scientific Inc...announced that its SeCore CDx HLA A Sequencing System has been granted 510(k) clearance by the United States Food and Drug Administration (FDA) for use as a companion diagnostic with TECELRA (afamitresgene autoleucel), Adaptimmune’s newly approved T-cell receptor (TCR) therapy for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. Synovial sarcoma is a rare, soft tissue cancer that most commonly impacts young adults."
    FDA event
    |
    SeCore CDx HLA Sequencing System
    |
    Tecelra (afamitresgene autoleucel)
    5ms
    Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy (Businesswire)
    "Agilent Technologies Inc...announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy."
    FDA event
    |
    MAGE-A4 IHC 1F9 pharmDx (SK032)
    |
    Tecelra (afamitresgene autoleucel)
    5ms
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy
    5ms
    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Baylor College of Medicine | Trial completion date: May 2024 --> May 2025
    Trial completion date
    |
    MultiTAA T cell therapy
    6ms
    ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov)
    P2, N=66, Recruiting, Adaptimmune | Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    7ms
    APOLLO: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=79, Recruiting, Marker Therapeutics, Inc. | N=37 --> 79
    Enrollment change
    7ms
    First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, CDR-Life AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CDR404
    8ms
    First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, CDR-Life AG
    New P1 trial
    |
    CDR404
    8ms
    In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager. (ASCO 2024)
    LUSC MAGE-A4HIGH tumors had a differentiated TiME profile. Our findings are consistent with an INFLAMLOWVASCLOW phenotype possibly indicative of an "immune desert" [Desbois et al 2020]. In contrast, LUAD MAGE-A4HIGH tumors had an INFLAMHIGHVASCLOW phenotype indicating that MAGE-A4 associations with TiME may be histology dependent in NSCLC.
    Clinical
    |
    CD8 (cluster of differentiation 8) • MAGEA4 (Melanoma antigen family A, 4)
    |
    Tempus xR
    |
    CDR404
    8ms
    ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) (clinicaltrials.gov)
    P2, N=3, Terminated, Adaptimmune | N=45 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Apr 2023; Study was terminated due to difficulty recruiting subjects and lack of efficacy
    Enrollment change • Trial termination • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    uzatresgene autoleucel (ADP-A2M4CD8)
    9ms
    Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. (PubMed, Lancet)
    Afami-cel treatment resulted in durable responses in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. This study shows that T-cell receptor therapy can be used to effectively target solid tumours and provides rationale to expand this approach to other solid malignancies.
    P2 data • Journal • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    ifosfamide • Tecelra (afamitresgene autoleucel)
    10ms
    SPEARHEAD-3 Pediatric Study (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Adaptimmune | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    10ms
    ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (clinicaltrials.gov)
    P1, N=120, Recruiting, Adaptimmune | Trial primary completion date: Sep 2023 --> Dec 2025
    Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    10ms
    IMC-C103C-101: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
    P1/2, N=75, Terminated, Immunocore Ltd | N=144 --> 75 | Trial completion date: Feb 2024 --> Sep 2023 | Active, not recruiting --> Terminated; The Sponsor terminated the study and there is no further enrollment. Endpoints will not be assessed for this trial.
    Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    |
    Tecentriq (atezolizumab) • IMC-C103C
    11ms
    MAGE-A4ᶜ¹º³²T for Multi-Tumor (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Adaptimmune | N=52 --> 71 | Trial completion date: Sep 2035 --> Sep 2032
    Enrollment change • Trial completion date • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A2 positive
    |
    Tecelra (afamitresgene autoleucel)
    11ms
    TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (clinicaltrials.gov)
    P1, N=7, Completed, Immatics US, Inc. | Active, not recruiting --> Completed | N=22 --> 7 | Trial completion date: Dec 2024 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • IO biomarker
    |
    cyclophosphamide • IMA201
    1year
    MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Peking University
    New P1 trial
    |
    cyclophosphamide
    1year
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Immatics Biotechnologies GmbH | Phase classification: P1a/1b --> P1
    Phase classification
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression • MAGEA4 overexpression
    |
    IMA401
    1year
    PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
    P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • pemetrexed • PDC*lung
    1year
    IMC-C103C-101: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
    P1/2, N=144, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Feb 2024 | Trial primary completion date: Jul 2025 --> Sep 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    |
    Tecentriq (atezolizumab) • IMC-C103C
    1year
    CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) (SITC 2023)
    Conclusions The high MAGE-A4 expression levels and the highly specific anti-cancer cell activity of CDR404 make it a highly attractive immunotherapy for development post-progression on ICI for patients with HLA-A*02:01+ SQ-NSCLC. A multi-tumor phase 1 trial of CDR404, including SQ-NSCLC, is expected to begin in 2024 with prospective patient selection for both HLA-A*02:01 and tumor MAGE-A4.
    IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    CDR404
    1year
    A novel ‘off the shelf’ TCR-NK cell therapy platform for the treatment of solid tumours: development of optimised MAGE-A4 targeting TCR-NK cells for advancement into the clinic (SITC 2023)
    Conclusions Taken together, these data demonstrate the feasibility and potential of generating optimised TCR-NK cells from PB-NK resulting in a highly potent cell product combining TCR-mediated and innate NK killing functions. Based on the potency and safety profile, ZI-MA4–1 has advanced into manufacturing with a preclinical package underway to enable a clinical trial for treatment of patients with advanced solid tumours.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • MAGEA4 (Melanoma antigen family A, 4)
    1year
    Development, validation and concordance of two MAGE-A4 immunohistochemistry (IHC) assays to establish prognostic value of MAGE-A4 expression in synovial sarcoma (SITC 2023)
    Conclusions The CLB MAGE-A4 immunostaining conditions were successfully adjusted and bridged to reach concordance with the clinical trial assay. This allowed the accurate assessment of the prognostic value of MAGE-A4 in SyS.
    Discordant
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    over1year
    PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
    P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • pemetrexed • PDC*lung
    over1year
    ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL") (CTOS 2023)
    Lymphodepleting chemotherapy consisting of fludarabine (30 mg/m^2/day for 4 days) and cyclophosphamide (600 mg/m^2/day for 3 days) will be administered beginning one week prior to afami-cel infusion... N/A. Submitting under Trials in Progress.
    Clinical • P1/2 data • IO biomarker • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression • MAGEA4 overexpression
    |
    cyclophosphamide • fludarabine IV • Tecelra (afamitresgene autoleucel)
    over1year
    SPEARHEAD-1: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Adaptimmune | N=90 --> 120 | Trial completion date: Nov 2034 --> Apr 2038
    Enrollment change • Trial completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    over1year
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
    P1, N=23, Terminated, Hoffmann-La Roche | N=260 --> 23 | Trial completion date: Feb 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Jul 2023; The study was terminated due to program discontinuation.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    Actemra IV (tocilizumab) • RG6129
    over1year
    Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager (ESMO 2023)
    Lack of response reported in another MAGE-A4 TCE trial (NCT03973333) where tumor screening in ovarian cancer was absent confirms that IHC selection will be essential for RNALOW tumors. In this regard, we have identified E7O1U as a highly specific MAGE-A4 antibody for precise IHC patient selection in the CDR404 trial.
    Clinical
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    CDR404
    over1year
    Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors (ESMO 2023)
    Nevertheless, inhibition of immunosuppressive pathways may improve anti-tumor responses; therefore, new SURPASS cohorts include ADP-A2M4CD8 combined with nivolumab or pembrolizumab. Data from additional pts treated by August 2023 will be presented. Conclusions ADP-A2M4CD8 continues to show an acceptable benefit-to-risk profile, including in pts receiving nivolumab combination therapy.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    over1year
    A Phase 2 Study (GOG-3084) Of ADP-A2M4CD8 TCR T-Cell Therapy, Alone Or In Combination With Nivolumab, In Patients With Recurrent Ovarian Cancers (ESGO 2023)
    Lymphodepletion chemotherapy (fludarabine 30 mg/m2/day for 4 days and cyclophosphamide 600 mg/m2/day for 3 days) will be followed by infusion of 1â10x10^9 ADP-A2M4CD8 T-cells. Adverse events will be monitored, with participants followed for 15 years from T-cell infusion. Conclusion SURPASS-3 is initiating in Q2 2023.
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule) • MAGEA4 (Melanoma antigen family A, 4)
    |
    CD8 expression • HLA-A*02 • HLA-A*02:01 + MAGEA4 expression • MAGEA4 expression
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV • uzatresgene autoleucel (ADP-A2M4CD8)
    over1year
    Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. (PubMed, Melanoma Res)
    This report suggests that afami-cel in combination with LDRT safely enhanced clinical benefit. This provides evidence for further exploring the benefit of LDRT in TCR-T cell therapy.
    Journal • Combination therapy
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Tecelra (afamitresgene autoleucel)
    over1year
    ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov)
    P2, N=66, Recruiting, Adaptimmune | Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Jun 2023
    Enrollment open • Trial initiation date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    over1year
    ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Adaptimmune | Trial primary completion date: Apr 2023 --> Dec 2023
    Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    uzatresgene autoleucel (ADP-A2M4CD8)
    over1year
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy